Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21436405 | 1.00 | NR3C1 (0.41) | NR3C1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL11197357 | 0.81 | KDM4E (0.37) | KDM4EALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL21436402 | 0.81 | KDM4E (0.37) | KDM4EALDH1A1MEN1KMT2ARAB9A | |
| SCHEMBL574692 | 0.79 | L3MBTL1 (0.40) | KDM4EALDH1A1MEN1KMT2AACLY | |
| SCHEMBL574691 | 0.79 | L3MBTL1 (0.40) | KDM4EALDH1A1MEN1KMT2AACLY | |
| SCHEMBL21436486 | 0.78 | VCAM1 (0.43) | KDM4EALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL21436487 | 0.78 | VCAM1 (0.43) | KDM4EALDH1A1MEN1KMT2AHPGD | |
| SCHEMBL21436403 | 0.77 | KDM4E (0.35) | KDM4EALDH1A1MEN1KMT2ALMNA | |
| SCHEMBL574057 | 0.74 | LPAR1 (0.39) | NR3C1KDM4EALDH1A1CNR2LMNA | |
| SCHEMBL574058 | 0.74 | LPAR1 (0.39) | NR3C1KDM4EALDH1A1CNR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112969692-A | Bumetanide derivatives for the treatment of hyperhidrosis | 兹伦汀公司 | 2021-06-15 | — | — | CN | disclosed |
| EP-3774763-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | ZILENTIN AG (CH) | 2021-02-17 | — | — | EP | disclosed |
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Zilentin AG (CH) | 2021-01-28 | — | — | US | disclosed |
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Zilentin AG (CH) | 2021-01-28 | — | — | US | disclosed |
| WO-2019193159-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | Universität Wien (AT) | 2019-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210022978-A1 | BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS | SLC9A1, SLC9A3, SLC5A1 | NR3C1 893/4885KDM4E 3838/4885ALDH1A1 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.